ATE239509T1 - Konjugate zur behandlung von prostatakrebs - Google Patents
Konjugate zur behandlung von prostatakrebsInfo
- Publication number
- ATE239509T1 ATE239509T1 AT97946296T AT97946296T ATE239509T1 AT E239509 T1 ATE239509 T1 AT E239509T1 AT 97946296 T AT97946296 T AT 97946296T AT 97946296 T AT97946296 T AT 97946296T AT E239509 T1 ATE239509 T1 AT E239509T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2922496P | 1996-10-30 | 1996-10-30 | |
| GBGB9626309.0A GB9626309D0 (en) | 1996-12-18 | 1996-12-18 | Conjugates useful in the treatment of prostate cancer |
| US4292197P | 1997-04-04 | 1997-04-04 | |
| GBGB9718160.6A GB9718160D0 (en) | 1997-08-28 | 1997-08-28 | Conjugates useful in the treatment of prostate cancer |
| PCT/US1997/019225 WO1998018493A2 (en) | 1996-10-30 | 1997-10-27 | Conjugates useful in the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE239509T1 true ATE239509T1 (de) | 2003-05-15 |
Family
ID=27451580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97946296T ATE239509T1 (de) | 1996-10-30 | 1997-10-27 | Konjugate zur behandlung von prostatakrebs |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0942754B1 (de) |
| JP (1) | JP2000509407A (de) |
| KR (1) | KR100508199B1 (de) |
| AR (1) | AR008907A1 (de) |
| AT (1) | ATE239509T1 (de) |
| AU (1) | AU726434B2 (de) |
| BG (1) | BG64768B1 (de) |
| BR (1) | BR9712589A (de) |
| CA (1) | CA2268738A1 (de) |
| CO (1) | CO4930281A1 (de) |
| CZ (1) | CZ155599A3 (de) |
| DE (1) | DE69721810T2 (de) |
| DK (1) | DK0942754T3 (de) |
| DZ (1) | DZ2333A1 (de) |
| EA (1) | EA002066B1 (de) |
| EE (1) | EE03858B1 (de) |
| ES (1) | ES2196374T3 (de) |
| HR (1) | HRP970566A2 (de) |
| HU (1) | HUP0000651A3 (de) |
| ID (1) | ID21358A (de) |
| IL (1) | IL129356A0 (de) |
| IS (1) | IS5025A (de) |
| NO (1) | NO992069L (de) |
| PE (1) | PE17399A1 (de) |
| PL (1) | PL333004A1 (de) |
| PT (1) | PT942754E (de) |
| SK (1) | SK57399A3 (de) |
| TR (1) | TR199901485T2 (de) |
| TW (1) | TW425286B (de) |
| WO (1) | WO1998018493A2 (de) |
| YU (1) | YU21399A (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9815116A (pt) * | 1997-12-02 | 2000-10-10 | Merck & Co Inc | Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna |
| CA2238257A1 (en) * | 1998-05-22 | 1999-11-22 | Universite De Montreal | Endocytosis of amf-r and uses thereof in cancer therapy |
| EP1098666B1 (de) * | 1998-07-17 | 2013-01-16 | The United States of America, represented by the Secretary, Department of Health and Human Services | Wasserlösliche arzneimittel und deren herstellungsmethode |
| US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| JP2003518000A (ja) * | 1998-12-11 | 2003-06-03 | コールター ファーマシューティカル，インコーポレイティド | プロドラッグ化合物およびその調製方法 |
| GB9924759D0 (en) * | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
| AU1094601A (en) * | 1999-10-19 | 2001-04-30 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| EP1228089A2 (de) * | 1999-10-27 | 2002-08-07 | Merck & Co., Inc. | Salzform eines konjugates zur behandlung von prostatakrebs |
| KR20030009388A (ko) | 2000-03-15 | 2003-01-29 | 브리스톨-마이어스 스퀴브 파마 컴파니 | 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도 |
| EP2316469A1 (de) * | 2002-02-22 | 2011-05-04 | Shire LLC | Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin |
| WO2005035003A2 (en) * | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| CN100372862C (zh) * | 2003-11-05 | 2008-03-05 | 天津和美生物技术有限公司 | 具有抗癌活性的阿霉素衍生物及其制备方法和应用 |
| WO2008067495A2 (en) * | 2006-11-29 | 2008-06-05 | Rutgers, The State University Of New Jersey | Chemotherapeutic conjugates and methods of use |
| CN101225094A (zh) * | 2007-01-18 | 2008-07-23 | 天津和美生物技术有限公司 | 具有抗癌活性的蒽醌四环类化合物 |
| BRPI1009521A2 (pt) * | 2009-03-09 | 2016-03-15 | Ktb Tumorforschungs Gmbh | pró-drogas. |
| CN110038135B (zh) | 2011-03-17 | 2021-03-05 | 伯明翰大学 | 重新定向的免疫治疗 |
| WO2013106643A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2016126611A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| DK3377103T4 (en) | 2015-11-19 | 2025-05-19 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| JP2023554520A (ja) | 2020-12-22 | 2023-12-27 | コビオレス エヌヴイ | テトラペプチド部分を含む化合物 |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| WO1997014416A1 (en) * | 1995-10-18 | 1997-04-24 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
-
1997
- 1997-10-24 HR HR9718160.6A patent/HRP970566A2/hr not_active Application Discontinuation
- 1997-10-27 IL IL12935697A patent/IL129356A0/xx not_active IP Right Cessation
- 1997-10-27 TR TR1999/01485T patent/TR199901485T2/xx unknown
- 1997-10-27 DE DE69721810T patent/DE69721810T2/de not_active Expired - Fee Related
- 1997-10-27 KR KR10-1999-7003846A patent/KR100508199B1/ko not_active Expired - Fee Related
- 1997-10-27 AT AT97946296T patent/ATE239509T1/de not_active IP Right Cessation
- 1997-10-27 WO PCT/US1997/019225 patent/WO1998018493A2/en not_active Ceased
- 1997-10-27 PT PT97946296T patent/PT942754E/pt unknown
- 1997-10-27 ES ES97946296T patent/ES2196374T3/es not_active Expired - Lifetime
- 1997-10-27 EE EEP199900179A patent/EE03858B1/xx not_active IP Right Cessation
- 1997-10-27 YU YU21399A patent/YU21399A/sh unknown
- 1997-10-27 EP EP97946296A patent/EP0942754B1/de not_active Expired - Lifetime
- 1997-10-27 ID IDW990259A patent/ID21358A/id unknown
- 1997-10-27 AU AU51497/98A patent/AU726434B2/en not_active Ceased
- 1997-10-27 CZ CZ991555A patent/CZ155599A3/cs unknown
- 1997-10-27 JP JP10520593A patent/JP2000509407A/ja not_active Ceased
- 1997-10-27 HU HU0000651A patent/HUP0000651A3/hu unknown
- 1997-10-27 DK DK97946296T patent/DK0942754T3/da active
- 1997-10-27 EA EA199900428A patent/EA002066B1/ru not_active IP Right Cessation
- 1997-10-27 CA CA002268738A patent/CA2268738A1/en not_active Abandoned
- 1997-10-27 SK SK573-99A patent/SK57399A3/sk unknown
- 1997-10-27 BR BR9712589-0A patent/BR9712589A/pt not_active Application Discontinuation
- 1997-10-27 PL PL97333004A patent/PL333004A1/xx unknown
- 1997-10-28 TW TW086115986A patent/TW425286B/zh not_active IP Right Cessation
- 1997-10-28 CO CO97063170A patent/CO4930281A1/es unknown
- 1997-10-29 AR ARP970105032A patent/AR008907A1/es not_active Application Discontinuation
- 1997-10-29 DZ DZ970183A patent/DZ2333A1/xx active
- 1997-10-29 PE PE1997000970A patent/PE17399A1/es not_active Application Discontinuation
-
1999
- 1999-04-13 IS IS5025A patent/IS5025A/is unknown
- 1999-04-29 NO NO992069A patent/NO992069L/no not_active Application Discontinuation
- 1999-05-26 BG BG103436A patent/BG64768B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
| NO20005864D0 (no) | Quinasoler til behandling av hjernesvulst | |
| EP0709090A3 (de) | Zusammensetzungen zur Behandlung von resistenten Tumoren | |
| NO971015L (no) | Forbindelser og metoder for behandling av cancer | |
| ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| NO984431D0 (no) | FremgangsmÕte for behandling av smerte | |
| DE60023982D1 (de) | System zur Behandlung von benigner Prostatahyperplasie | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| EP0926955A4 (de) | Konjugate nützlich in die behandlung von prostatakarzinom | |
| FI972484L (fi) | Karsinooman hoito | |
| DE60030554D1 (de) | Verwendungen von et743 zur behandlung von krebs | |
| EP1320376A4 (de) | Behandlung von prostatakrebs | |
| NO20022245D0 (no) | Onkolyttiske kombinasjoner for behandling av cancer | |
| IS5035A (is) | Aðferðir til varnar gegn brjóstakrabbameini | |
| DZ2665A1 (fr) | Conjugués utiles pour le traitement du cancer de la prostate. | |
| DE69729004D1 (de) | Photodynamische therapie zur behandlung von osteosrthritis | |
| ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
| NO984446D0 (no) | FremgangsmÕte for behandling av smerte | |
| ATE250580T1 (de) | Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie | |
| DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
| NO981822L (no) | Anvendelse av proteinet GAX for behandling av cancer | |
| NO984189D0 (no) | Fremgangsmåte for behandling av bipolar forstyrrelse | |
| DE69806062D1 (de) | Kombinationstherapie zur behandlung von aids | |
| ATE204167T1 (de) | Antikonvulsive derivate zur behandlung von psoriasis | |
| DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0942754 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |